Cancer Advisor

Introduction: Why This Debate Matters Right Now The metabolic theory of cancer is exploding in popularity. Professor Tom Seyfried has become a household name among patients seeking alternatives to conventional oncology, thanks to his groundbreaking book Cancer as a Metabolic Disease and the press-pulse strategy built around glucose and glutamine restriction. But in May 2026, Jane McLelland —bestselling author of How to Starve Cancer and a stage 4 cancer survivor who reversed her own disease—published an interesting Substack titled “ Beyond Warburg: What Tom Seyfried Gets Right — And the Blind Spot That Could Cost Your Patient. ” This isn’t a takedown. It’s a respectful, evidence-based extension that could save lives by highlighting a critical limitation in the “keto-for-everyone” approach. If you’re exploring ketogenic diet cancer protocols, repurposed drugs, or metabolic therapies, this article breaks it all down with actionable insights into the metabolic theory of canc...

Introduction: Early Detection Saves Lives In July 2023, a routine mammogram changed everything for Dr. Kelly Victory. Despite leading a healthy lifestyle — exercising regularly, eating a low‑sugar diet, and avoiding smoking — a small lump was detected. Early detection, swift action, and a proactive approach were key to her journey toward recovery. “Even when you feel healthy, cancer doesn’t always send warnings. Early screening can be lifesaving.” — Dr. Kelly Victory Dr Kelly Victory, discusses February as National Cancer Prevention Month on Fox News , emphasizing metabolic and immune health for lowering cancer risks . For decades, cancer has been framed as sudden. Random. Unpredictable. But that story is incomplete. Cancer doesn’t start overnight. It develops quietly — reinforced by daily habits. Chronic stress. Poor sleep. Processed diets. Sedentary routines. Environmental toxins. Modern life often works against the body’s natural defenses. And while not all cancers are preventable,...

Introduction: Why Some Cancers Become Metabolic “Power Users” In Part 1, we introduced the Warburg Effect and explained how many cancers shift their energy production away from efficient mitochondrial respiration toward accelerated glucose fermentation. While this metabolic shift is present in many tumor types, it is not uniform across all cancers. In fact, one of the most consistent findings in cancer metabolism research is that the most aggressive and treatment-resistant cancers often display the strongest Warburg phenotype . These tumors consume glucose at extremely high rates, convert it into lactate even in oxygen-rich conditions, and reshape their surrounding environment to support continuous growth and invasion. This metabolic reprogramming is not a passive consequence of cancer—it is an active survival strategy. By rewiring pathways such as PI3K-AKT-mTOR signaling, c-Myc activation, HIF-1α stabilization, GLUT1 overexpression, and Hexokinase-2 upregulation , cancer cel...

Researchers in Australia have discovered that melittin, the main active component of honeybee venom, can rapidly destroy aggressive breast cancer cells in laboratory studies. The findings, published in Nature's journal  npj Precision Oncology , have generated worldwide interest because melittin appeared capable of killing difficult-to-treat breast cancer cells while causing comparatively less damage to normal cells. Although the research remains in the preclinical stage and human clinical trials have not yet been completed, the study highlights the growing potential of naturally derived compounds in oncology research. Key Takeaways Honeybee venom contains melittin, a biologically active peptide with anticancer properties. Laboratory studies showed rapid destruction of triple-negative and HER2-positive breast cancer cells. Melittin disrupted cancer cell membranes and blocked growth-promoting signaling pathways. Synthetic melittin produced similar results, reducing the nee...

William Makis; Ilyes Baghli; Pierrick Martinez (Corresponding Author) Case Rep Oncol (2025) 18 (1): 856–863. https://doi.org/10.1159/000546362 PubMed: 40605964 Abstract Background:  Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.  Case Presentations:  This report highlights 3 cases of patients with advanced cancer – including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorp...